Delgado A, Soriano I, Sánchez E, Oliva M, Evora C
Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de La Laguna, La Laguna, Spain.
Eur J Pharm Biopharm. 2000 Sep;50(2):227-36. doi: 10.1016/s0939-6411(00)00109-0.
The effect on lung accumulation of modifying the surface compositions of (99m)Tc poly(lactide-co-glycolide) (PLGA) and (99m)Tc poly(ethylene glycol)-poly(lactide-co-glycolide) (PEG-PLGA) microspheres with different surfactants was assessed after intravenous injection into rats. Microspheres were prepared with PLGA or PEG-PLGA by the emulsion solvent evaporation method using polyvinyl alcohol (PVA), polyethylene glycol (PEG), albumin (BSA) or poloxamer 188 as surfactant, in the external aqueous phase. Commercial human albumin microspheres (Sferotec((R)), HAM) were used as reference. According to the European Pharmacopeia, >80% of (99m)Tc-HAM in the size range 10-50 microm, must be accumulated in the lung 15 min after intravenous administration. By modifying the surfactant, the resulting lung accumulation was 99% for (99m)Tc-HAM, and more than 50% for PLGA microspheres prepared with poloxamer 188 (1 and 4%), reaching 67% with 8% Poloxamer 188 and around 30-39% for PLGA and PEG-PLGA microspheres prepared with the other surfactants. PLGA microspheres made with 8% poloxamer 188 gave good quality lung images under a gamma camera for the first few minutes, subsequently liver radioactivity masked lung images.
将不同表面活性剂修饰的(99m)锝聚(丙交酯-乙交酯)(PLGA)和(99m)锝聚(乙二醇)-聚(丙交酯-乙交酯)(PEG-PLGA)微球静脉注射到大鼠体内后,评估其对肺部聚集的影响。采用乳液溶剂蒸发法,以聚乙烯醇(PVA)、聚乙二醇(PEG)、白蛋白(BSA)或泊洛沙姆188作为表面活性剂,在外部水相中用PLGA或PEG-PLGA制备微球。使用市售人白蛋白微球(Sferotec®,HAM)作为对照。根据欧洲药典,粒径范围为10-50微米的(99m)锝-HAM在静脉给药后15分钟内,必须有>80%聚集在肺部。通过改变表面活性剂,(99m)锝-HAM的肺部聚集率为99%,用1%和4%泊洛沙姆188制备的PLGA微球的肺部聚集率超过50%,8%泊洛沙姆188制备的PLGA微球的肺部聚集率达到67%,用其他表面活性剂制备的PLGA和PEG-PLGA微球的肺部聚集率约为30-39%。用8%泊洛沙姆188制备的PLGA微球在γ相机下最初几分钟能获得质量良好的肺部图像,随后肝脏放射性掩盖了肺部图像。